o	Nykode's APC targeted vaccine technology can be delivered as mRNA and generate
strong  T cell responses
o	Nykode's APC targeted vaccine technology consistently results in faster,
broader and stronger immune response compared to non-targeted vaccines, whether
delivered as DNA or mRNA


Oslo, Norway, October 9, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced it is presenting at the
annual mRNA Cancer Vaccines Summit in Boston, Massachusetts on October 12th.
 
Mikkel W. Pedersen, Chief Scientific Officer at Nykode will present preclinical
data highlighting the differentiating factors of Nykode's proprietary vaccine
technology. When delivered either via DNA or mRNA, Nykode's Antigen presenting
cells (APC)-targeted cancer vaccines lead to a faster and broader T cell
response compared to standard mRNA vaccines with identical antigens in a
head-to-head comparison. There is almost a doubling of the number of antigens
that are immunogenic when targeted to APCs, and the responses are primarily
driven by CD8 T cells.

"These data demonstrate the strength of Nykode's APC targeted technology to
drive relevant T cell responses for cancer immunotherapy whether we use the DNA
or mRNA format.  Simultaneous induction of CD8 T cell responses to multiple
different cancer-specific antigens holds the key to successful anti-cancer
immune interventions. It is exciting to see that our unique mechanism of action
targeting tumor antigens to APC leads to this unique and differentiated
response," says Mikkel W. Pedersen.

"We are very excited with these data showing that whether delivered as DNA or
mRNA, Nykode's technology results in superior immune responses. We now see the
potential of Nykode's vaccine technology to also improve the current mRNA cancer
vaccines" says Michael Engsig, CEO of Nykode. "Combined with the long and
durable responses observed to date in our clinical trials applying Nykode's
vaccines as DNA, we are very optimistic about the future broad application of
the Vaccibody platform in the development of cancer vaccines."

Details for the Nykode Therapeutics' presentation are as follows:
Title: Opportunities to improve mRNA Cancer Vaccines
Time & Date: 10.00am ET, October 12, 2023


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on treatment
of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to APC, which have been shown to induce broad,
strong and long-lasting antigen specific immune responses which correlates with
clinical responses in cancer.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer